← All trials
NCT00395135
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2006
- Primary completion
- Feb 1, 2009
- Completion date
- Feb 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 3182
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Arena PharmaceuticalsLead sponsor
- Georgetown UniversityOverall official - principal investigator
- Arena PharmaceuticalsStudy director
- University of VermontOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.